Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.12, FiscalAI reports. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.73 million.
Celldex Therapeutics Price Performance
Shares of NASDAQ:CLDX traded up $0.15 during trading on Friday, hitting $41.71. The company had a trading volume of 808,912 shares, compared to its average volume of 954,386. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of -9.59 and a beta of 0.87. The company has a fifty day simple moving average of $35.19 and a two-hundred day simple moving average of $31.54. Celldex Therapeutics has a one year low of $19.72 and a one year high of $42.92.
Institutional Trading of Celldex Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after buying an additional 680 shares during the period. Millennium Management LLC lifted its holdings in shares of Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after acquiring an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after acquiring an additional 14,979 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares during the period. Finally, Hsbc Holdings PLC bought a new position in Celldex Therapeutics during the 2nd quarter valued at about $347,000.
Analyst Ratings Changes
View Our Latest Stock Report on CLDX
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.
Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.
Featured Stories
- Five stocks we like better than Celldex Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
